Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

(2013) J.-A. Losman et al.   SCIENCE

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

(2012) A. T. Fathi et al.   BLOOD

Disruption of Wild-Type IDH1 Suppresses D-2-Hydroxyglutarate Production in IDH1-Mutated Gliomas

(2012) G. Jin et al.   CANCER RESEARCH

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

(2012) Peppi Koivunen et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

(2012) Masato Sasaki et al.   NATURE

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG

(2011) Beth Pietrak et al.   BIOCHEMISTRY

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

(2011) N. Boissel et al.   BLOOD

Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors

(2011) E. Pronier et al.   BLOOD

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

(2011) Rasheduzzaman Chowdhury et al.   EMBO REPORTS

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H

(2010) Bei Yang et al.   CELL RESEARCH

Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group

(2010) Nicolas Boissel et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

(2010) Stefan Gross et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2010) Lenny Dang et al.   NATURE

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

(2010) K E Yen et al.   ONCOGENE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

Structural studies ofSaccharomyces cerevesiaemitochondrial NADP-dependent isocitrate dehydrogenase in different enzymatic states reveal substantial conformational changes during the catalytic reaction

(2008) Yingjie Peng et al.   PROTEIN SCIENCE